Radiation zaps heart arrhythmia: 4-Year study launches

NCT ID NCT06744530

First seen Apr 30, 2026 · Last updated Jun 23, 2026 · Updated 6 times

Summary

This study tracks 50 people with a severe, hard-to-treat heart rhythm problem called ventricular tachycardia. They receive a single, high-dose radiation treatment (STAR) aimed at the heart tissue causing the trouble. Researchers will monitor how well the treatment controls the abnormal rhythm and affects quality of life over 48 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENTRICULAR TACHYCARDIA (VT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • UZ Leuven

    RECRUITING

    Leuven, 3000, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

stereotactic radiotherapy ablation (STAR)

What this could lead to

If successful, this could confirm STAR as a safe and effective long-term option for controlling ventricular tachycardia when other treatments fail.

What could go wrong

This is an observational study with no control group, so results may not prove cause and effect. Long-term safety and effectiveness are still being evaluated.

Conditions

The condition(s) this trial relates to.

ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.